(vianews) - lna sante (lna.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| lna sante (lna.pa) | €19.56 | 2.54% | 9.08% |
| equasens (eqs.pa) | €53.00 | 1.88% | 27.25% |
| ucb (ucb.br) | €86.88 | 1.52% | 3.7% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. lna sante (lna.pa)
2.54% forward dividend yield and 9.08% return on equity
lna santé sa engages in the management and operation of health establishments. the company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. lna santé sa was founded in 1990 and is based in vertou, france.
earnings per share
as for profitability, lna sante has a trailing twelve months eps of €2.28.
pe ratio
lna sante has a trailing twelve months price to earnings ratio of 8.58. meaning, the purchaser of the share is investing €8.58 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.08%.
volume
today's last reported volume for lna sante is 645 which is 85.95% below its average volume of 4592.
dividend yield
as claimed by morningstar, inc., the next dividend payment is on jul 6, 2023, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.54%.
yearly top and bottom value
lna sante's stock is valued at €19.56 at 01:30 est, way below its 52-week high of €34.00 and higher than its 52-week low of €19.00.
moving average
lna sante's worth is way under its 50-day moving average of €25.38 and way below its 200-day moving average of €28.85.more news about lna sante.
2. equasens (eqs.pa)
1.88% forward dividend yield and 27.25% return on equity
equasens société anonyme provides healthcare it solutions in europe. it offers id. patient, a business software; id. mobility, a back-office management software; pandalab pro, an instant messaging solution; id. vente, an has-certified drug database; id. commande, an order management module; dispensing robots; services ségur id; id. dosage, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; visiodroits module; and website connector. the company also provides id. desk, an informative and interactive dashboard; id. up!, a real-time monitoring and control application of id management software; id. easyq, a queue management solution; miaterapia; id. show, an application for managing real-time communications on pharmacy screens; pharmaweb; tsgatepro; lmo, a dispensary business software; and lgo, a dispensary management software. in addition, it offers domilink had software; mobisoins mobility tool; memorialis, support software for alzheimer's monitoring teams; hospilink, an hospital information system applications; hospilink dpi, a computerized patient file; hospilink lookup big data; enephro solutions; noviacare solutions; kap&link2, a contact chip card reader terminal and nfc reader; es-kap-ad, a connected nomadic tool incorporating software; kap-inside, a mobile terminal; and ti-kap allowing access to contact and contactless cards. further, the company provides authenticator, a patented authentication system; kap'teur by kapelse, a patented universal sensor; expressvitale; médistory, that automates the transfer of invoicing to the healthcare professional's accounting. additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. the company was incorporated in 1996 and is headquartered in villers-les-nancy, france. equasens société anonyme is a subsidiary of marque verte sante.
earnings per share
as for profitability, equasens has a trailing twelve months eps of €3.05.
pe ratio
equasens has a trailing twelve months price to earnings ratio of 17.38. meaning, the purchaser of the share is investing €17.38 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.25%.
volatility
equasens's last week, last month's, and last quarter's current intraday variation average was a negative 1.03%, a negative 0.58%, and a positive 2.00%.
equasens's highest amplitude of average volatility was 2.77% (last week), 1.61% (last month), and 2.00% (last quarter).
yearly top and bottom value
equasens's stock is valued at €53.00 at 01:30 est, below its 52-week low of €55.00.
more news about equasens.
3. ucb (ucb.br)
1.52% forward dividend yield and 3.7% return on equity
ucb sa, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. the company's primary products include cimzia for inflammatory tnf mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; vimpat, keppra, and briviact for epilepsy; neupro for parkinson's disease and restless legs syndrome; nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and zyrtec and xyzal for allergies. it also offers evenity for the treatment of osteoporosis in postmenopausal women; bimzelx for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. in addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; bepranemab to treat alzheimer's disease; and ucb0599 to treat parkinson's disease. further, it engages in contract manufacturing activities. ucb sa has collaboration agreements with amgen, biogen, roche/genentech, novartis, otsuka, and doc.ai. it operates in the united states, japan, germany, rest of europe, spain, france, china, italy, the united kingdom, ireland, belgium, and internationally. the company was incorporated in 1925 and is headquartered in brussels, belgium.
earnings per share
as for profitability, ucb has a trailing twelve months eps of €1.7.
pe ratio
ucb has a trailing twelve months price to earnings ratio of 51.11. meaning, the purchaser of the share is investing €51.11 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.7%.
volume
today's last reported volume for ucb is 95693 which is 70.83% below its average volume of 328132.
dividend yield
according to morningstar, inc., the next dividend payment is on apr 28, 2023, the estimated forward annual dividend rate is 1.33 and the estimated forward annual dividend yield is 1.52%.
moving average
ucb's worth is way higher than its 50-day moving average of €76.85 and above its 200-day moving average of €79.58.more news about ucb.